Cullinan Therapeutics, Inc. (CGEM) Dividend History

Company News

• Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

  Cullinan Therapeutics received approval from the European Medicines Agency to initiate a Phase 1 trial of its bispecific CD19 T cell engager CLN-978 in patients with rheumatoid arthritis. The trial will be conducted at research institutions in Germany and Italy, and CLN-978 is also being studied for systemic lupus erythematosus.

  GlobeNewswire Inc.
• Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

  Amgen's rocatinlimab outperformed placebo in an atopic dermatitis trial, but the data fell short of market leader Dupixent's results, raising concerns about its competitiveness. Uplizna, Amgen's treatment for myasthenia gravis, showed promising results in a Phase 3 trial, with potential advantages like less frequent dosing.

  Benzinga

  Featured Companies: AMGN REGN
• Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

  Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

  Zacks Investment Research

  Featured Companies: VTRS
• Why Shares of Cullinan Oncology Jumped This Week

  The company's presentation at a conference got the attention of analysts and investors.

  The Motley Fool
• Cullinan: Trading Way Below Cash

  Cullinan is trading way below cash, which often means the market thinks the company lacks growth prospects. Read more to see why I rate CGEM stock a Hold.

  Seeking Alpha